Patent Number: 7,030,111

Title: Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA damaging treatments

Abstract: The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are used to treat proliferative disorders such as cancer. The invention provides compositions and methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA-damaging agents and treatments.

Inventors: Kawabe; Takumi (Numazu, JP), Kobayashi; Hidetaka (Numazu, JP)

Assignee: Canbas Co., Ltd.

International Classification: A61K 31/5375 (20060101); A61K 31/495 (20060101); C07D 241/04 (20060101); C07D 265/30 (20060101)

Expiration Date: 4/18/02018